Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > New lows….what is next?
View:
Post by Pareto8020 on Nov 01, 2023 10:22am

New lows….what is next?

Seven and a half cents.  Brutal....just brutal.

What is the shareprice going to look like come December with tax loss selling?  If there was ever a candidate for tax loss selling it is Sirona.

With a market cap of under $19M why wouldn't Allergan just buy Sirona out and save themselves millions and millions in royalties?
Comment by moneycollector on Nov 01, 2023 3:09pm
Would you as a shareholder accept a buyout offer of 19M or 7.5cents?
Comment by biorun on Nov 01, 2023 3:33pm
Yeah, not going to happen. Buy low sell high.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities